- In chronic lymphocytic leukemia (CLL), frontline ibrutinib monotherapy was associated with longer time to next treatment (TTNT) vs chemoimmunotherapy (CIT), including bendamustine+rituximab (BR).
- Ibrutinib was associated with overall savings when factoring in medical costs.
Why this matters
- Ibrutinib has demonstrated favorable outcomes vs CIT regimens; however, some concerns persist regarding ibrutinib’s high pharmacy cost.
- Study to compare TTNT and costs in patients with CLL who received frontline ibrutinib monotherapy (n=322) or CIT (n=839) including BR (n=455).
- Funding: Janssen Scientific Affairs LLC.
- At 24 months follow-up, patients were significantly less likely to begin a subsequent line of therapy with ibrutinib monotherapy vs:
- CIT: HR, 0.54; 95% CI, 0.33-0.90; P=.0163.
- BR: HR, 0.54; 95% CI, 0.32-0.92; P=.0208.
- Patients receiving frontline ibrutinib experienced fewer monthly days with outpatient visits: rate ratio, 0.75; P=.0200.
- Ibrutinib was associated with higher pharmacy costs; however, these were dramatically offset by lower medical costs, resulting in a net mean monthly all-cause cost savings of $3766 (P<.0001 vs cit and br.>
- Patients receiving ibrutinib may have been more likely to have unfavorable cytogenetics.